Treating Recurrent Tricuspid Regurgitation and Iatrogenic Atrial Septal Defect
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Heterotopic caval valve implantation may be a reasonable option for alleviating symptoms in select high-risk patients with recurrent tricuspid regurgitation after failed interventional tricuspid valve repair. However, altered right atrial hemodynamic status should be considered in procedural planning to avoid potential right-left shunting in cases of septal defects. ().
References
1.
Abdul-Jawad Altisent O, Benetis R, Rumbinaite E, Mizarien V, Codina P, Gual-Capllonch F
. Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation. J Clin Med. 2021; 10(19).
PMC: 8509289.
DOI: 10.3390/jcm10194601.
View
2.
Toyama K, Rader F, Kar S, Kubo S, Shiota T, Nishioka T
. Iatrogenic Atrial Septal Defect After Percutaneous Mitral Valve Repair With the MitraClip System. Am J Cardiol. 2017; 121(4):475-479.
DOI: 10.1016/j.amjcard.2017.11.006.
View
3.
Russo M, Di Mauro M, Saitto G, Lio A, Berretta P, Taramasso M
. Beating Versus Arrested Heart Isolated Tricuspid Valve Surgery: Long-term Outcomes. Ann Thorac Surg. 2021; 113(2):585-592.
DOI: 10.1016/j.athoracsur.2021.03.070.
View
4.
Russo M, Saitto G, Lio A, Di Mauro M, Berretta P, Taramasso M
. Observed versus predicted mortality after isolated tricuspid valve surgery. J Card Surg. 2022; 37(7):1959-1966.
PMC: 9325428.
DOI: 10.1111/jocs.16483.
View
5.
Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos I, Cruz-Gonzalez I, Baz J, Pascual I
. 6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation: The TRICUS EURO Study. JACC Cardiovasc Interv. 2022; 15(13):1366-1377.
DOI: 10.1016/j.jcin.2022.05.022.
View